Tweedy Browne Co LLC Cuts Holdings in Johnson & Johnson (NYSE:JNJ)

Tweedy Browne Co LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,043,724 shares of the company’s stock after selling 3,255 shares during the period. Johnson & Johnson accounts for about 9.4% of Tweedy Browne Co LLC’s investment portfolio, making the stock its 3rd biggest holding. Tweedy Browne Co LLC owned 0.08% of Johnson & Johnson worth $264,417,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Phocas Financial Corp. increased its stake in shares of Johnson & Johnson by 999,928.6% during the second quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock valued at $1,743,000 after acquiring an additional 125,161,066 shares during the period. Nuveen Asset Management LLC increased its stake in shares of Johnson & Johnson by 5,447.1% during the second quarter. Nuveen Asset Management LLC now owns 16,924,656 shares of the company’s stock valued at $2,357,266,000 after acquiring an additional 16,619,550 shares during the period. Thoroughbred Financial Services LLC increased its stake in shares of Johnson & Johnson by 14,147.0% during the second quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock valued at $401,425,000 after acquiring an additional 3,986,071 shares during the period. Renaissance Technologies LLC increased its stake in shares of Johnson & Johnson by 145.5% during the second quarter. Renaissance Technologies LLC now owns 4,341,162 shares of the company’s stock valued at $604,637,000 after acquiring an additional 2,572,695 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Johnson & Johnson by 11.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 20,791,713 shares of the company’s stock valued at $2,895,870,000 after acquiring an additional 2,204,757 shares during the period. 72.25% of the stock is currently owned by institutional investors.

Shares of NYSE:JNJ traded up $1.57 during trading on Friday, reaching $133.00. 4,856,974 shares of the company traded hands, compared to its average volume of 7,224,392. The firm has a fifty day simple moving average of $130.83 and a 200 day simple moving average of $134.05. The firm has a market cap of $343.25 billion, a P/E ratio of 16.26, a price-to-earnings-growth ratio of 2.20 and a beta of 0.69. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99. The company has a quick ratio of 1.00, a current ratio of 1.26 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.00 by $0.12. The company had revenue of $20.73 billion during the quarter, compared to analyst estimates of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter last year, the business posted $2.05 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 8.65 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 2.86%. The ex-dividend date of this dividend is Monday, November 25th. Johnson & Johnson’s payout ratio is presently 46.45%.

JNJ has been the topic of several recent research reports. Sanford C. Bernstein upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target on the stock in a research report on Friday, October 11th. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $158.00 to $163.00 in a research report on Thursday, October 24th. Atlantic Securities upgraded shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research report on Wednesday, October 16th. Wells Fargo & Co decreased their price target on shares of Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 16th. Finally, Zacks Investment Research upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 price target on the stock in a research report on Thursday, October 17th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $151.64.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Derivative

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply